Elutia Posts Narrower Loss in Fiscal Q2
Elutia (NASDAQ:ELUT), a medical technology company specializing in biologic products for device protection and surgical reconstruction, released its second-quarter earnings on August 14, 2025, reporting results for the period ended June 30. The company saw its bottom-line loss per share narrow compared to the same period last year, but operating losses increased due to higher litigation expenses. Revenue came in at $6.26 million, just below the analyst consensus of $6.55 million, and was nearly unchanged from the prior year. The quarter reflected a mix of progress and ongoing challenges, with notable growth in EluPro and margin gains, while declines in other product lines and persistent losses highlighted areas for improvement.
Source: Analyst estimates provided by FactSet.
Elutia develops biologic-based medical products that protect implantable devices from infection and support soft-tissue reconstruction. Its main revenue drivers are device protection products, such as the BioEnvelope family, and regenerative matrices for women’s health and soft tissue repair.
Source Fool.com
